新型Au (I) -和Ag (I) -NHC复合物与N-Boc-保护的素作为神经退行性疾病的潜在候选者
Jessica Ceramella1, Assunta D'Amato2, Francesca Procopio3
1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via Pietro Bucci, 87036 Arcavacata di Rende, Italy.
International journal of molecular sciences
|July 12, 2025
概括
新的黄金和白银复合物通过抑制关键酶和减少炎症来治疗神经退行性疾病具有前景. 这些新型金属药物为阿尔茨海默氏症和帕金森病等疾病提供了潜在的新疗法途径.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 像阿尔茨海默氏症和帕金森氏症这样的神经退行性疾病 (NDD) 是一个主要的健康负担.
- 关键的病理特征包括氧化应激,神经炎症和神经递质失衡.
- 针对胆和单氨基系统的现有治疗方法存在局限性,需要新的治疗策略.
研究的目的:
- 设计,合成和评估新的黄金 (I) 和银 (I) N-异环碳素 (NHC) 复合物.
- 研究这些复合物作为乙胆酶 (AChE) 和单胺氧化酶 (MAO) 抑制剂的潜力.
- 评估它们的抗氧化和抗炎性质,用于NDD管理.
主要方法:
- 新型黄金 (I) 和银 (I) NHC复合物的合成.
- 在 silico 和 in vitro 生物活性评估.
- 对酶抑制 (AChE,MAO),抗氧化和抗炎作用的评估.
主要成果:
- 合成的Au (I) 和Ag (I) 复合物得到了表征.
- 预先的in silico和in vitro数据表明对ACHE和MAO的抑制潜力.
- 这些复合物表现出抗氧化和抗炎活性.
结论:
- 新型的黄金 (I) 和白银 (I) NHC复合体显示出作为NDD的多目标剂的潜力.
- 这些化合物需要进一步研究,作为神经退行性疾病的治疗候选物.
- 这项研究为探索NDD治疗中的金属药物开辟了新的途径.
相关概念视频
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263


